IMA-203

HonorHealth Research Institute has treated the first patient in a 50-site international Phase III clinical trial testing IMA203 TCR-T, the world's first T cell receptor therapy targeting PRAME in melanoma.

IMA203, a PRAME-targeting T-cell therapy, shows frequent and durable responses in melanoma and other solid tumors, according to the phase 1 IMA203-101 study.

Immatics' ACTengine IMA203 TCR-T therapy shows a confirmed objective response rate exceeding 50% in heavily pretreated melanoma patients.

Immatics' IMA203, a T cell receptor-based therapy, demonstrated a confirmed response in over half of melanoma patients in an early-stage trial.

IMA203, a PRAME-targeted T-cell therapy, demonstrated a 54% objective response rate in pretreated metastatic melanoma patients.